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a  b  s  t  r  a  c  t
Uliginosin  B, a  phloroglucinol  isolated  from  Hypericum  polyanthemum  Klotzsch  ex  Reichardt,  Hyperi-
caceae,  has  antidepressant-like  effect  in the  forced  swimming  test  in  rodents  and  inhibits  monoamines
neuronal  reuptake  without  binding  to their  neuronal  carriers.  Studies  showed  the  involvement  of Na+,K+-
ATPase  brain  activity  in  depressive  disorders,  as  well  as  the  dependence  of neuronal  monoamine  transport
from  Na+ gradient  generated  by Na+,K+-ATPase.  This  study  aimed  at evaluating  the effect  of uliginosin  B  on
Na+,K+-ATPase  activity  in  mice  cerebral  cortex  and hippocampus  (1 and  3 h  after  the  last  administration)
as  well  as the  inﬂuence  of veratrine,  a  Na+ channel  opener,  on  the antidepressant-like  effect  of uliginosin
B.  Mice  were  treated  (p.o.)  with  uliginosin  B single  (10 mg/kg)  or repeated  doses  (10 mg/kg/day,  3  days).
Acute  administration  reduced  the immobility  in  the  forced  swimming  test  and  tail  suspension  test  and
increased  Na+,K+-ATPase  activity  in  cerebral  cortex  1 h after  treating,  whereas  the  repeated  treatment
induced  the  antidepressant-like  effect  and  increased  the  Na+,K+-ATPase  activity  at  both  times  evaluated.
None  treatment  affected  the  hippocampus  enzyme  activity.  Veratrine  pretreatment  prevented  uliginosin
B antidepressant-like  effect  in  the  forced  swimming  test,  suggesting  the  involvement  of  Na+ balance  reg-
ulation  on this  effect. Altogether,  these  data  indicate  that  uliginosin  B  reduces  the  monoamine  uptake  by
altering  Na+ gradient.
© 2016  Sociedade  Brasileira  de Farmacognosia.  Published  by Elsevier  Editora  Ltda.  This  is  an open
access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).ntroduction
Based on the well-known efﬁcacy of Hypericum perforatum (St.
ohn’s wort herb) for the treatment of mild to moderate depression
Linde, 2009) our group has been studying chemical and phar-
acological features of South Brazilian Hypericum species (Daudt
t al., 2000; Ferraz et al., 2002; Viana, 2007; Viana et al., 2003, 2005,
006, 2008; Stein et al., 2012). Hypericum polyanthemum Klotzsch
x Reichardt, Hypericaceae, extracts have shown antinociceptive
Viana et al., 2003; Haas et al., 2010) and antidepressant-like effects
n rats and mice (Stein et al., 2012). Its major chemical constituents
∗ Corresponding author.
E-mail: stela.rates@ufrgs.br (S.M. Rates).
http://dx.doi.org/10.1016/j.bjp.2016.04.005
102-695X/© 2016 Sociedade Brasileira de Farmacognosia. Published by Elsevier Edit
reativecommons.org/licenses/by-nc-nd/4.0/).are three benzopyrans, named HP1 (6-isobutyryl-5,7-dimethoxy-2,
2-dimethyl-benzopyran), HP2 (hydroxy-6-isobutyryl-5-methoxy-
2,2-dimethyl-benzopyran) and HP3 (5-hydroxy-6-isobutyryl-
7-methoxy-2,2-dimethyl-benzopyran), and a phloroglucinol
derivative, uliginosin B (Von Poser et al., 2006). Uliginosin B (1)
has a dimeric structure consisting of phloroglucinol and ﬁlicinic
acid moieties (Rocha et al., 1995; Nör et al., 2004; Duarte et al.,
2014), and seems to be responsible for the antidepressant-like
effects observed in animals behavioral tests (Stein et al., 2012).
This compound showed antidepressant-like effect in the forced
swimming test in mice, which was  prevented by the impairment of
the monoaminergic neurotransmission in vivo; it also inhibited the
sinaptossomal uptake of dopamine, noradrenaline and serotonin,
but interestingly it did not interact with their respective site on
neuronal carriers (Stein et al., 2012). These ﬁndings suggest that
ora Ltda. This is an open access article under the CC BY-NC-ND license (http://
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liginosin B acts by a distinct mechanism than the classical antide-
ressant drugs, which act by blocking monoamine transporters.
O
O
OH
OHHO
O
O
OH
1
Monoamine transporters are located in the plasma membrane
nd are driven by the electrochemical gradient of Na+ generated by
a+,K+-ATPase (Nelson and Lill, 1994). It has been shown that some
ntidepressants, such as amitriptyline, nortriptyline, imipramine
nd desipramine, inhibit the Na+,K+-ATPase activity (Carfagna and
uhoberac, 1993; Sanganahalli et al., 2000; Viola and Arnaiz, 2007).
n the other hand, dopamine, noradrenaline and serotonin are
ble to stimulate the activity of this enzyme (Viola and Arnaiz,
007).
Na+,K+-ATPase activity is essential to the brain normal function,
ince the ﬂow of Na+ and K+ ions across the membrane is necessary
o neuronal excitability, regulation of osmotic balance, cell volume
nd intracellular transport of molecules linked to the co-transport
f Na+, such as glucose, amino acids and neurotransmitters (Kaplan,
002; Jorgensen et al., 2003). Several experimental studies have
escribed the involvement of Na+,K+-ATPase brain activity in the
epressive disorders (Zanatta et al., 2001; Gamaro et al., 2003;
asconcellos et al., 2005; Acker et al., 2009). Mania and bipolar
epression have been associated with increased intracellular Na+
oncentrations (Li and El-Mallakh, 2004). Rats exposed to chronic
ariable stress (CVS) developed despair-like endophenotypes and
ad decreased hippocampal and amygdalar Na+,K+-ATPase activ-
ty (Crema et al., 2010). The antidepressant ﬂuoxetine and the
ood stabilizer lithium simultaneously prevented despair induced
y CVS and prevented the decrease in Na+,K+-ATPase activity
Vasconcellos et al., 2005).
The observation that several neuroactive drugs act on Na+
hannels also indicates the importance of Na+ gradient in brain
isorders neurobiology. Sodium channels are voltage-dependent
ransmembrane proteins responsible for the increase of permeabil-
ty to sodium, which initiates and propagates the action potential
n excitable cells (Cestèle and Catterall, 2000; Bourin et al., 2009).
he Na+ channels are targets to different classes of drugs such as
nticonvulsants, local anesthetics and antiarrhythmics (Rasgdale
t al., 1996). Some anticonvulsants (carbamazepine, lamotrigine,
henytoin, topiramate, valproate sodium) are also used to treat
ipolar disorder (Reinares et al., 2012) and lamotrigine has been
sed specially to treat bipolar depression (Leng et al., 2013).
In this context, the aim of the present study was  to evaluate
he effect of the acute and sub-acute administration of uliginosin
 on Na+,K+-ATPase activity in mice cerebral cortex and hip-
ocampus and the involvement of sodium channels in uliginosin
 antidepressant-like effect.
aterials and methods
lant materialHypericum polyanthemum Klotzsch ex Reichardt, Hypericaceae
erial parts were collected at Cac¸ apava do Sul, in the state of
io Grande do Sul – Brazil (October, 2008). The voucher speci-
ens were deposited at the herbarium of the Federal Universityrmacognosia 26 (2016) 611–618
of Rio Grande do Sul (ICN Bordignon, 3118 Herbário do Departa-
mento de Botânica – Instituto de Biociências – UFRGS). The plant
collection was  authorized by IBAMA (Instituto Brasileiro do Meio
Ambiente e dos Recursos Naturais Renováveis) (n◦ 003/2008; Pro-
tocol 02000.001717/2008 – 60).
Preparation of extract
H. polyanthemum lipophilic extract was  obtained from dried
and powdered plant material (300 g) extracted with cyclohexane
(plant/solvent ratio 1:10, w/v) by static maceration for 48 h. The
extract was  evaporated to dryness under reduced pressure at 45 ◦C
to eliminate the solvent, yielding a free solvent extract termed POL
(3.5%). Then, the extract was  treated with acetone to remove the
waxes, according to Rocha et al. (1994), producing an insoluble
residue, which was  eliminated by ﬁltering with paper ﬁlter.
Characterization of the extract by HPLC and uliginosin B isolation
The extract was dissolved in HPLC grade methanol (2 mg/ml),
ﬁltered (0.22 m pore size, Merck) and analyzed by high perfor-
mance liquid chromatography Water HPLC system (Milford, MA,
USA). Uliginosin B (1) determination was carried out with an iso-
cratic solvent condition (95% CH3CN, 5% H2O, 0.01% TFA) through a
Waters Nova-Pack C18 column (4 m,  3.9 mm × 150 mm)  adapted
to a guard column Waters Nova-Pack C18 60A (3.9 mm × 20 mm),
ﬂow rate of 1 ml  min−1 and UV detection at 220 nm,  according to
the method previously described (Nunes et al., 2009). Uliginosin B
concentration was determined as 16%, isolated by means of prepar-
ative thin layer and column chromatography and ﬁnally identiﬁed
by 1H–13C NMR  as described elsewhere (Rocha et al., 1995; Ferraz
et al., 2002; Nör et al., 2004).
Animals
Behavioral and biochemical tests were carried out with male CF1
mice (25–30 g) purchased from Fundac¸ ão Estadual de Produc¸ ão e
Pesquisa em Saúde, RS (Brazil). The animals were housed by ﬁve
in plastic cages (17 cm × 28 cm × 13 cm)  and were kept under a
12 h light/dark cycle (lights on at 7 a.m.) at constant temperature
of 23 ± 1 ◦C with free access to standard certiﬁed rodent diet and
tap water. All experimental protocols were approved by The Ani-
mal  Care Local Ethical Committee (CEUA UFRGS; Protocol 18518),
and performed according to Brazilian law (Brazil, 2008), which
are in compliance with the European Communities Council Direc-
tive of 24 November 1986 (86/609/EEC) and International Guiding
Principles for Biomedical Research Involving Animals (Bankowski,
1985).
Experimental design
Mice (n = 8 per group) were treated by gavage (10 ml/kg) with
uliginosin B (1) acutely (10 mg/kg, p.o.) or sub-acutely (10 mg/kg,
p.o., once a day, during 3 days), based on previous results of our
group (Viana et al., 2008). Control groups were performed for both
treatment regimens and the animals were treated with vehicle
(saline + polisorbate 80 2.0%). Different groups were used for bio-
chemical and behavioral experiments (tail suspension test, TST –
and forced swimming test, FST).
Time-course of uliginosin B antidepressant-like effect on the
TST and FST was evaluated by testing independent groups of
mice which were acutely or repeatedly treated with uliginosin
B (10 mg/kg, p.o.) or vehicle. The animals were evaluated in the
behavioral assays only once after treatment. Measurement of
Na+,K+-ATPase activity was  performed using animals that were
not submitted to any behavioral test: different groups (acutely or
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epeatedly treated) were euthanized by decapitation 1 or 3 h after
eceiving the last drug administration and brain structures were
emoved immediately.
In another set of experiments, we investigated the possible con-
ribution of sodium channels to uliginosin B antidepressant-like
ffect. We  evaluated the inﬂuence of the pre-treatment with ver-
trine, a Na+ channel opener, on the FST. Initially, dose-response
xperiments were performed in the FST and locomotor activity in
rder to determine the dose of veratrine to be used: veratrine (0.06,
.125 and 0.5 mg/kg, i.p.)  was administered 45 min  before the test.
he sub effective dose was deﬁned as the dose not able to reduce
mmobility in the FST and with no effect on locomotor activity
Centurião et al., 2014). The association of veratrine and uliginosin B
onsisted of the pretreatment with veratrine (0.06 mg/kg) or vehi-
le, i.p.,  45 min  before the FST, plus uliginosin B or vehicle, p.o.,
0 min  before the test.
ssays
issue preparation
Cerebral cortex and hippocampus were homogenized in 10 vol-
mes (1:10, w/v) of 0.32 mM sucrose solution containing 5 mM
EPES and 1 mM EDTA, pH 7.5. The homogenates were centrifuged
t 1000 × g for 10 min  and the supernatants were removed for
a+,K+-ATPase activity determination.
a+,K+-ATPase activity assay
The reaction mixture for Na+,K+-ATPase assay contained 5 mM
gCl2, 80 mM NaCl, 20 mM KCl, and 40 mM Tris–HCl, pH 7.4, in a
nal volume of 200 l. After 10 min  of pre-incubation at 37 ◦C, the
eaction was initiated by the addition of ATP to a ﬁnal concentration
f 3 mM,  and incubated for 20 min. Controls were carried out under
he same conditions with the addition of 1 mM ouabain. Na+,K+-
TPase activity was calculated by the difference between the two
ssays according to the method described by Wyse et al. (2000).
eleased inorganic phosphate (Pi) was measured by the method of
ham et al. (1986). Speciﬁc activity of the enzyme was expressed
s nmol Pi released per min  per mg  of protein.
rotein determination
Protein concentration was determined by the Bradford method
1976) using bovine serum albumin as standard.
ehavioral experiments
ail suspension test (TST)
The TST was conducted according to Steru et al. (1985) with
inor modiﬁcations (Müller et al., 2012). Mice were adapted to
he laboratory conditions 1 h before the experiment. Animals were
uspended by tail 60 cm above the ﬂoor using adhesive tape (1 cm
rom the tip of the end) in a dim light room. Immobility time was
ecorded (in seconds) by a blind to treatment observer during 6 min.
ice were considered immobile when they hung passively and
ompletely motionless.
orced swimming test (FST)
The FST was carried out according to Porsolt et al. (1978) with
inor modiﬁcations standardized and validated in our laboratory
Viana et al., 2005). Mice were adapted to the laboratory conditions
 h before being exposed to the FST. The animals were individu-
lly forced to swim in a cylinder pool (10 cm diameter, 13 cm high,
ater at 22 ± 1 ◦C) and the total time of immobility during 6 min
as scored (in seconds). Immobility time was recorded when the
ouse remained ﬂoating motionless or making only the move-
ents necessary to keep its head above water.rmacognosia 26 (2016) 611–618 613
Locomotor activity
The spontaneous locomotor activity was performed in the
open-ﬁeld (Viana et al., 2005). Forty-ﬁve minutes after the
administration, mice were placed in a transparent acrylic box
measuring 45 cm × 30 cm × 30 cm with a dark bottom divided into
24 equal quadrants. They were evaluated during 10 min, after
5 min  habituation. The number of crossings was recorded by an
observer blinded to treatments.
Statistical analysis
Data were expressed as mean + SEM of the mean. Data from
biochemical analysis were analyzed by Student’s t test. Behavioral
experiments data were analyzed by one-way or two-way ANOVA
followed by Student–Newman–Keuls. Differences were considered
statistically signiﬁcant at p < 0.05. The statistical procedures were
performed using the Sigma Stat software 2.03 (Jandel Scientiﬁc
Corporation).
Results
Acute administration of uliginosin B increased Na+,K+-ATPase
activity in cerebral cortex 1 h after treatment [t (9) = 2.447, p < 0.05]
(Fig. 1A), but not after 3 h [t (8) = 0.323, p = 0.755] (Fig. 1B). In the
hippocampus, Na+,K+-ATPase activity was not altered at both times
studied: 1 h [t (9) = 0.898, p = 0.393] (Fig. 1C) and 3 h [t (8) = 1.155,
p = 0.281] (Fig. 1D).
Sub-acute administration of uliginosin B increased Na+,K+-
ATPase activity in cerebral cortex 1 h after the last administration
[t (10) = 3.300, p < 0.01] (Fig. 2A), as well as 3 h after [t (9) = 2.518,
p < 0.05] (Fig. 2B). No alterations were veriﬁed in the hippocampus
at the two  different times: 1 h [t (10) = 1.494, p = 0.166] (Fig. 2C) and
3 h [t (8) = 0.788, p = 0.449] (Fig. 2D).
The acute administration of uliginosin B (10 mg/kg, p.o.) in the
TST and FST are shown in Fig. 3. One-way ANOVA showed a signiﬁ-
cant effect of uliginosin B administration in the TST [F(2,25) = 4.411;
p < 0.05]; post hoc analysis indicated a reduction on the immo-
bility time at 1 h (p < 0.05), but not at 3 h after administration
(p = 0.079) when compared to the control group (Fig. 3A). The
same effect was  observed when animals were submitted to the FST
[F(2,30) = 11.136; p < 0.001]: post hoc analysis indicated a signiﬁcant
decrease in the immobility time 1 h after administration (p = 0.076),
but not after 3 h (p > 0.05) (Fig. 3B).
The effect of sub-acute administration of uliginosin B
(10 mg/kg/day, p.o.) is shown in Fig. 3C. One-way ANOVA revealed
a signiﬁcant effect of uliginosin B [F(2,21) = 6.360; p < 0.01] and
post hoc analysis indicated a signiﬁcant anti-immobility effect at
1 h (p < 0.01) and 3 h (p < 0.05) after the last administration when
compared to control group.
The anti-immobility effect of uliginosin B (10 mg/kg, p.o.) was
prevented by the pretreatment with veratrine (0.06 mg/kg, i.p.)
[two-way ANOVA: Fpre-treatment × treatment(1,31) = 6,205, p = 0.019]
(Fig. 4). The co-administration of veratrine and uliginosin B has
no effect when compared to the uliginosin B and vehicle (Tween),
thus veratrine affect the antidepressant-like effect of uliginosin B
in mouse FST.
Discussion
In the present study, we demonstrated that uliginosin B, the
main phloroglucinol derivative from H. polyanthemum, increases
activity of Na+,K+-ATPase in mice cerebral cortex, but not in
hippocampus. This effect was  treatment regimen dependent,
being sustainable only in animals that were repeatedly treated.
The same temporal activity proﬁle was observed in the TST and
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Fig. 1. Effect of the acute administration of uliginosin B on brain Na+,K+-ATPase activity. Mice were acutely treated with uliginosin B (10 mg/kg, p.o.) and euthanized by
decapitation 1 or 3 h after the last administration; immediately cerebral cortex and hippocampus were removed to measure enzyme activity. Student t test; values are
expressed as mean + SEM (n = 5–6). Difference from Control *p < 0.05.
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Fig. 2. Effect of the sub-acute treatment of uliginosin B on brain Na+,K+-ATPase activity. Mice were repeatedly treated with uliginosin B (10 mg/kg/day, 3 days, p.o.) and
euthanized by decapitation 1 or 3 h after the last administration; immediately cerebral cortex and hippocampus were removed to measure enzyme activity. Student t test;
values  are expressed as mean + SEM (n = 6). Difference from Control *p < 0.05.
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Fig. 3. Effect of the acute and sub-acute treatment of uliginosin B (10 mg/kg, p.o.)
on  the immobility time. Mice were acutely treated with uliginosin B and submitted
to  test, 1 or 3 h after administration: tail suspension test (TST, panel A) and forced
swimming test (FST, panel B); mice were treated for 3 days, once a day and submitted
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Fig. 4. Effect of the pretreatment of mice with veratrine (0.06, mg/kg i.p.) on
the  anti-immobility effect of uliginosin B (10 mg/kg, p.o.) in the FST. Indepen-
dent groups of mice were pretreated (i.p.) with vehicle (saline + polisorbate 80
2%  = tween) and treated (p.o.) with vehicle (Tween – Control group) or uliginosin
B  (Tween – Uliginosin B group); or pretreated (i.p.) with veratrine and treated (p.o.)
with vehicle (Veratrine – Control group) or uliginosin B (Veratrine – Uliginosin B
group). Values expressed as mean + SEM (n = 8–10). Two-way ANOVA followed by
Student–Newman–Keuls. * Difference from Tween – Uliginosin B versus Tween –tudent–Newman–Keuls; values are expressed as mean + SEM (n = 8–10). Difference
rom Control *p < 0.05, **p  < 0.01.
ST suggesting that the uliginosin B effect is, at least in part, due
o its action on Na+,K+-ATPase. Furthermore, the pretreatment
ith veratrine, a Na+ channel opener, prevented the uliginosin B
ntidepressant-like effect, reinforcing that the activity of uliginosin
 involves the regulation of Na+ balance.
Depression is deﬁned clinically as a pathological complex of
sychological, neuroendocrine and somatic symptoms that cannot
e reproduced in animals. However, in mice, speciﬁc measur-
ble behaviors’ can be assayed such as FST and TST which are aControl, p < 0.05. @Difference from Tween – Uliginosin B versus Veratrine – Uligi-
nosin B, p < 0.05.
good screening tools with good reliability and predictive validity
(Petit-Demouliere et al., 2005; Cryan et al., 2005; Castagné et al.,
2009). The effect of uliginosin B in reducing immobility time in
the TST and FST reinforces our previous results that have already
demonstrated the antidepressant-like effect of this phlorogluci-
nol derivative (Stein et al., 2012). In addition, in this study we
moved on the possible mode of action of uliginosin B by study-
ing its effect on the enzyme Na+,K+-ATPase. Clinical (Goldstein
et al., 2006, 2009; Tochigi et al., 2008) and preclinical studies
(Acker et al., 2009; Gamaro et al., 2003; Vasconcellos et al., 2005;
Crema et al., 2010; Kirshenbaum et al., 2011) reported that Na+,K+-
ATPase is diminished in depressive disorders. Gamaro et al. (2003)
demonstrated that the Na+,K+-ATPase activity decreased in rats
hippocampus subjected to chronic stress model of depression,
effect that was reversed by the repeated treatment with ﬂuoxetine
and lithium (Vasconcellos et al., 2005), whereas tricyclic antide-
pressants inhibited the enzyme activity (Sanganahalli et al., 2000).
Although the animals were not subjected to any depression
model, the results showed that uliginosin B increased Na+,K+-
ATPase activity in cerebral cortex about 18% 1 h after the last
administration, but it did not alter the enzyme activity after 3 h.
In the sub-acute treatment, uliginosin B was able to increase in
20% the enzyme activity 1 and 3 h after the last administration,
suggesting a longstanding effect of the repeated treatment (for
3 days). These ﬁndings are consistent with Zanatta et al. (2001),
who demonstrated that the chronic administration of ﬂuoxetine
(14 days) increases the enzyme activity, fact that can contribute to
ﬂuoxetine therapeutic efﬁcacy.
On the other hand, none of the uliginosin B treatment regimens
(acute and sub-acute) have changed the enzyme activity in the
hippocampus. Morphological and neurochemical alterations have
been reported in the hippocampus of depressed patients (Sheline
et al., 2003). Thus, the lack of the effect of uliginosin B on the
Na+,K+-ATPase activity in mice hippocampus may  be due the fact
that the animals were not submitted to any experimental model
of chronic depression. This ﬁnding also suggests a selective effect
of uliginison B on cortical Na+,K+-ATPase, which could be particu-
larly relevant, since this brain structure is involved in depression
neurobiology (Price and Drevets, 2010) and post mortem studies
have demonstrated alterations on Na+,K+-ATPase activity in the
cortex of depressed patients (Goldstein et al., 2006). Noteworthy,
in a previous study our group has found similar results (Müller
et al., 2015), where the Na+,K+-ATPase activity was increased in
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Calabrese, J.R., Huffman, R.F., White, R.L., Edwards, S., Thompson, T.R., Ascher, J.A.,
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he cortex, but not in the hippocampus, of animals treated with
alepotriates. We  speculate that this proﬁle could be related to the
rregular distribution of Na+,K+-ATPase isoenzymes. Three  iso-
orms are abundant in the brain: 1, expressed by neurons and glia;
2, predominant in glia; and 3, neuronal (McGrail et al., 1991).
ochigi et al. (2008) studied the gene expression pattern in post-
ortem brains of subjects with major depression and found that
a+,K+-ATPase 3 gene expression is decreased in prefrontal cor-
ex of subjects with major and bipolar depression. Another study
ith Na+,K+-ATPase 3 heterozygous mice showed a reduction of
5% in neuronal Na+,K+-ATPase activity. We  speculate that this
roﬁle could be related to the irregular distribution of Na+,K+-
TPase isoenzymes. Three  isoforms are abundant in the brain:
1, expressed by neurons and glia; 2, predominant in glia; and
3, neuronal (McGrail et al., 1991). Tochigi et al. (2008) stud-
ed the gene expression pattern in postmortem brains of subjects
ith major depression and found that Na+,K+-ATPase 3 gene
xpression is decreased in prefrontal cortex of subjects with major
nd bipolar depression. Another study with Na+,K+-ATPase 3
eterozygous mice showed a reduction of 15% in neuronal Na+,K+-
TPase activity. Furthermore, these animals were vulnerable to
evelop increased depression-like endophenotypes in a chronic
ariable stress model (Kirshenbaum et al., 2011). These data sug-
est that Na+,K+-ATPase 3 in cerebral cortex could be a target
o new antidepressant drugs and to study the pathophysiology of
epressive disorders.
The pre-treatment with veratrine prevented the anti-
mmobility effect of uliginosin B in the FST, effect that is in
ine with the literature, which demonstrated a similar proﬁle to
yperbrasilol B (Centurião et al., 2014), hyperforin (Codagnone
t al., 2007) and lamotrigine (Calabrese et al., 2008; Prica et al.,
008; Bourin et al., 2009). A recent study from our group showed
hat hyperbrasilol B, a natural dimeric phloroglucinol derivative
rom H. caprifoliatum, also had its anti-immobility effect prevented
y veratrine, and it was able to increase Na+,K+-ATPase activity in
ice hippocampus, but not cerebral cortex (Centurião et al., 2014).
yperforin, a phloroglucinol derivative from H. perforatum, which
s an European species worldwide used for depression, seems
o exert its antidepressant action by mechanisms dependent
n Na+ channels, without altering the activity of Na+,K+-ATPase
Chatterjee et al., 1998a,b). In addition, hyperforin inhibits the
euptake of monoamines without binding to their transporters
Wonnemann et al., 2000). Several authors demonstrated the
resence of a carrier-mediated monoamine transport mechanism,
esponsible for the entrance of dopamine, norepinephrine and
erotonin in the nerve terminal, accompanied by Na+ ions (Xhaard
t al., 2008; Kristensen et al., 2011) mechanism abolished in the
bsence of Na+ (Krueger, 1990; Gu et al., 1994; Piﬂ et al., 1997).
amotrigine, in turn, is an anti-epiletic agent used at bipolar
epression to maintenance treatment. It acts by stabilizing the
resynaptic membrane through the blockade of voltage-gated Na+
hannels (Codagnone et al., 2007). Vitezic et al. (2008) demon-
trated a partial protective effect of lamotrigine on the inhibition
f Na+,K+-ATPase activity induced by kainic acid in rats prefrontal
ortex and hippocampus. Also, Southam et al. (1998) demon-
trated in vitro that lamotrigine inhibits the reuptake of serotonin,
orepinephrine and dopamine, reinforcing the involvement of
odium gradient (Xhaard et al., 2008).
Considering the effect of uliginosin B on the activity of Na+,K+-
TPase and on Na+ channels together with previous studies of
ur group demonstrating that uliginosin B inhibits the reuptake
f monoamines in a different manner from most antidepressants
Stein et al., 2012) we can speculate that uliginosin B reduces the
onoamine uptake by altering Na+ gradient.
In conclusion, the present study represents one step ahead in the
lucidation of the mechanism of action of the antidepressant-likermacognosia 26 (2016) 611–618
activity of uliginosin B, a natural phloroglucinol derivative, suggest-
ing that involvement of uliginosin B in regulation of Na+ balance
may  occur through increased of Na+,K+-ATPase activity. The reg-
ulatory mechanism involving Na+ may  be regarded an important
property for antidepressant-like activity of this phloroglucinol
derivative.
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